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Intracellular tyrosine kinases as novel targets for anti-fibrotic
therapy in systemic sclerosis
J. H. W. Distler1 and O. Distler2
Tissue fibrosis is a major cause of death in SSc, but therapies that target selectively fibrosis are not yet available for routine clinical use.
Recent pre-clinical studies suggest that selective tyrosine kinase inhibitors that target c-Abl, PDGF receptor or Src kinases might be
promising targets for anti-fibrotic approaches. Dual inhibition of c-Abl and PDGF receptor by imatinib and nilotinib, and inhibition of Src
kinases either selectively by SU6656 or in combination with c-Abl and PDGF by dasatinib exerted potent anti-fibrotic effects. Imatinib,
nilotinib, dasatinib and SU6656 reduced dose-dependently the synthesis of extracellular matrix protein in human dermal fibroblasts in vitro
and prevented fibrosis in the mouse model of bleomycin-induced skin fibrosis. Clinical data from patients with chronic myelogenous
leukaemia suggest that imatinib, nilotinib and dasatinib are well tolerated. Based on the promising pre-clinical data, imatinib is currently
evaluated in clinical trials for the treatment of fibrosis in SSc and trials with other tyrosine kinase inhibitors are in preparation.
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Tissue fibrosis is a major cause of morbidity and mortality in SSc.
Anti-fibrotic therapies that target selectively the activation of
fibroblasts and the increased production of extracellular matrix
(ECM) are not yet available. Recently, selective inhibitors of
intracellular tyrosine kinases have been evaluated as novel anti-
fibrotic approaches.
Imatinib mesylate (STI571, Gleevec/Glivec, Novartis) is a
small molecule tyrosine kinase inhibitor that binds competitively
to the ATP-binding pocket of abelson kinase (c-Abl) and thereby
blocks efficiently its tyrosine kinase activity, which requires
transition of ATP into ADP and phosphorylation of target
proteins. c-Abl is an important downstream signalling molecule of
TGF- and PDGF [1]. In cells deficient for c-Abl, the induction of
ECM proteins by TGF- is strongly decreased. Of note, the
activation of c-Abl by TGF- is independent of Smad3 as the
stimulation of c-Abl by TGF- was not reduced in cells deficient
for Smad3. In addition to its effects on c-Abl, imatinib mesylate
interferes also with PDGF signalling by blocking the tyrosine
kinase activity of PDGF receptors. Imatinib inhibits also the
tyrosine kinase activity of the gene product of the proto-oncogene
c-kit and of c-fms. Thus, imatinib targets simultaneously and
selectively two major pro-fibrotic pathways activated in SSc.
Imatinib is widely used for the treatment of bcr-Abl-positive
chronic myelogenous leukaemia and gastrointestinal stromal
tumours with more 100 000 patients treated so far. Imatinib
possesses favourable pharmacokinetic properties as it is well
absorbed after oral administration and has to be taken only once
daily.
We could demonstrate that imatinib strongly inhibited the
synthesis of collagen 1a1, collagen 1a2 and fibronectin-1 by
dermal fibroblasts by up to 90% in pharmacologically relevant
concentrations [2]. Furthermore, treatment with imatinib pre-
vented efficiently the development of fibrosis in the mouse model
of bleomycin-induced dermal fibrosis with reduced dermal
thickness, number of myofibroblasts and decreased synthesis of
ECM in lesional skin. Smaller clinical case series suggested also
that treatment of patients with chronic myeloid leukaemia (CML)
might lead to a regression of concomitant bone marrow
fibrosis [3]. While the mechanisms of bone marrow fibrosis are
different from skin and organ fibrosis in SSc, the anti-fibrotic
effect of imatinib did not correlate with the cytogenetic response,
suggesting that the anti-fibrotic effects were independent from the
suppression of cancer cells [3]. Imatinib mesylate might therefore
not only prevent the progression of fibrosis in SSc patients, but
might also be effective for the treatment of established fibrosis.
This reflects the clinical situation, where patients usually present
with at least partially established fibrosis.
Most recently, nilotinib (Tasigna, Novartis) and dasatinib
(Spyrcel, Bristol-Myers Squibb), two novel inhibitors of Abl-
kinases and PDGF receptors have been approved for the treat-
ment of bcr-Abl-positive chronic myelogenous leukaemia with
resistance or intolerance to imatinib. Nilotinib and dasatinib
are also small molecule tyrosine kinase inhibitors, which can be
administered orally [4, 5]. Like imatinib, nilotinib inhibits
selectively the tyrosine kinase activity of Abl-kinases, PDGF
receptor and c-kit. Dasatinib targets additionally the structurally
related family of Src kinases. Both, nilotinib and dasatinib inhibit
the activity of Abl significantly more potent than imatinib and
are effective in most cell lines resistant to imatinib. The spectra of
adverse effects of dasatinib and nilotinib differ from that of
imatinib and patients with intolerance to imatinib can often
be switched safely to nilotinib or dasatinib. We demonstrated
recently that dasatinib and nilotinib both potently inhibit the
production of ECM proteins in dermal fibroblasts and the
development of fibrosis upon bleomycin challenge [6]. Thus,
dasatinib and nilotinib might be interesting candidates for the
treatment of patients who cannot tolerate imatinib.
This might be particular due for the combined Abl/Src inhibitor
dasatinib, because we could demonstrate recently that Src kinases
play an important role for the synthesis of ECM in SSc [7]. Src
kinases are activated by pro-fibrotic cytokines such as TGF- or
PDGF in SSc fibroblasts. Inhibition of Src kinases by chemical
inhibitors or overexpression of a dominant negative mutant of Src
and the endogenous antagonist csk reduced strongly the synthesis
of ECM proteins by dermal fibroblasts. Furthermore, treatment
of mice with the specific inhibitor of Src kinases SU6656 reduced
dose-dependently the dermal thickness and the collagen content in
lesional skin in the mouse model of bleomycin-induced dermal
fibrosis. Thus, Src kinases might also represent interesting novel
targets for anti-fibrotic therapeutic approaches in SSc.
Abl kinase inhibitors have been shown to be well tolerated in
clinical trials with CML patients with adverse side effects leading
to the discontinuation of the drug in <1% of the patients.
However, mild side-effects are frequent and outside of clinical
trials, up to 30% of the patients discontinue imatinib because
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of adverse effects. The major adverse events responsible for
discontinuation are dose-dependent and include oedema, muscle
cramps, diarrhoea and bone marrow toxicity. Furthermore, Abl-
kinase inhibitors might induce congestive heart failure. Recently,
10 patients have been reported, who developed congestive heart
failure while on imatinib [8]. Histological evaluation of cardiac
sections suggested a toxic cardiomyopathy. However, the inter-
pretation of this report is complicated by the fact that the majority
of patients reported with congestive heart failure while on
imatinib had pre-existing cardiac disease or cardiovascular risk
factors and that cardiotoxicity occurred only in 10 patients out of
more than 100 000 patients treated with imatinib. Nevertheless,
this potential side-effect needs special attention in the ongoing
clinical trials in patients with SSc.
A particular concern of the use of tyrosine kinase inhibitors in
SSc are anti-angiogenic side-effects. Vascular disease is a major
feature of SSc and might be further aggravate by drugs that
interfere with angiogenesis. Imatinib, nilotinib and dasatinib all
inhibit the tyrosine kinase activity of PDGF receptor. As PDGF
signalling is crucial for pericyte survival and as pericyte coverage
is essential to stabilize new vessel, inhibition of PDGF receptor
tyrosine kinase activity might inhibit angiogenesis [9]. However,
PDGF signalling is up-regulated and overactivation of pericytes
might play a role for both the vascular and fibrotic disease in SSc.
Moreover, PDGF plays a crucial role in the pathogenesis of
pulmonary arterial hypertension. Thus, treatment with the
aforementioned tyrosine kinase inhibitors might exert beneficial
effects by decreasing PDGF signalling to normal levels. Src
kinases have also been implicated in endothelial cell functions and
angiogenesis. VEGF activates Src in avian endothelial cells and
overexpression of a dominant negative Src mutant inhibited
VEGF-induced vascular permeabilization and angiogenesis. Thus,
Src mediates VEGF-induced angiogenesis under normal circum-
stances. However, an uncontrolled overexpression of VEGF has
been demonstrated in SSc patients. The uncontrolled overexpres-
sion of VEGF has deleterious rather than beneficial effects on
angiogenesis that might further aggravate the vascular disease in
SSc. Inhibition of Src signalling might therefore help to control
the dysregulated activation of VEGF signalling and its negative
effects on angiogenesis in SSc. Taken together, the net effect of
Abl/PDGFR and Src inhibitors on angiogenesis in SSc is unclear
and needs further investigation.
The mechanisms for tissue fibrosis and wound healing are
similar in that fibroblast activation and increased production
of ECM play central roles in both processes. Thus, anti-fibrotic
therapies might also inhibit wound healing. Indeed, imatinib
mesylate has recently been shown to interfere with the recruitment
of pericytes and fibroblasts and wound closure in murine model of
wound healing [10].
In summary, several lines of evidence suggest that Abl/
PDGFR- and Src kinase inhibitors such as imatinib, nilotinib,
dasatinib and SU6656 inhibit rather specifically fibroblast activa-
tion and synthesis of ECM and exert potent anti-fibrotic poten-
tials. First clinical trials with imatinib mesylate for the treatment of
fibrosis in SSc are currently ongoing and trials with other tyrosine
kinase inhibitors are in preparation. The results of these trials
might have great impact on the treatment of fibrotic diseases.
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Rheumatology key messages
 Imatinib mesylate is a small molecule tyrosine kinase inhibitor that
blocks TGF- and PDGF signalling pathways.
 Imatinib mesylate showed potent anti-fibrotic affects in pre-clinical
models including the bleomycin skin fibrosis model.
 Other clinically available c-Abl-kinase inhibitors with similar effects
in pre-clinical fibrosis models include dasatinib and nilotinib
 c-Abl-kinase inhibitors are well tolerated in oncological diseases
such as bcr-Abl-positive chronic myelogenous leukaemia with
relatively rare severe side-effects, but rather frequent mild
side-effects.
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